Newland Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Operating Revenue	663.43	719.43	643.85	621.21	508.93	429.75
Other Revenue	7	7	7.59	6.15	4.91	3.38
Revenue	670.43	726.44	651.44	627.36	513.84	433.12
Revenue Growth (YoY)	-4.03%	11.51%	3.84%	22.09%	18.63%	6.54%
Cost of Revenue	429.2	437.43	392.84	404.01	307.82	236.31
Gross Profit	241.23	289	258.6	223.36	206.02	196.81
Selling, General & Admin	55.48	47.62	44.49	38.83	31.56	25.3
Research & Development	53.65	55.49	51.96	30	20.59	20.62
Other Operating Expenses	6.51	2.71	3.89	6.99	6.4	5.83
Operating Expenses	115.18	108.1	96.75	78.04	69.69	53.99
Operating Income	126.05	180.91	161.85	145.31	136.33	142.82
Interest Expense	-0.06	-0.09	-0.13	-6.88	-6.71	-3.8
Interest & Investment Income	12.83	16.7	19.63	1.34	0.26	0.08
Currency Exchange Gain (Loss)	0.25	0.25	0.06	0.29	-0.13	-0.35
Other Non Operating Income (Expenses)	3.65	-0.06	-0.12	-0.09	-0.06	-0.02
EBT Excluding Unusual Items	142.71	197.7	181.29	139.97	129.69	138.74
Gain (Loss) on Sale of Investments	-1.09	-0.23	0.04	1.36	0.17	-
Gain (Loss) on Sale of Assets	-	-	0.07	-0.44	-0.21	-0.12
Asset Writedown	-3.36	-2.62	-1.46	-0.32	-0.11	-
Legal Settlements	-	-	-	-	-	-3
Other Unusual Items	1.86	2.5	1.22	2.31	2.4	1.81
Pretax Income	140.12	197.35	181.16	142.88	131.94	137.43
Income Tax Expense	17.72	24.34	23.96	11.17	17.11	18.97
Earnings From Continuing Operations	122.41	173.01	157.2	131.71	114.82	118.46
Minority Interest in Earnings	1.31	0.62	1.78	0.6	0.15	-
Net Income	123.72	173.63	158.98	132.3	114.98	118.46
Net Income to Common	123.72	173.63	158.98	132.3	114.98	118.46
Net Income Growth	-24.61%	9.21%	20.16%	15.07%	-2.94%	8.52%
Shares Outstanding (Basic)	392	392	391	302	294	292
Shares Outstanding (Diluted)	392	392	391	302	294	292
Shares Change (YoY)	0.39%	0.39%	29.52%	2.59%	0.64%	0.34%
EPS (Basic)	0.32	0.44	0.41	0.44	0.39	0.41
EPS (Diluted)	0.32	0.44	0.41	0.44	0.39	0.40
EPS Growth	-24.91%	8.79%	-7.22%	12.17%	-3.36%	8.18%
Free Cash Flow	16.5	15.97	162.94	8.5	23.68	30.9
Free Cash Flow Per Share	0.04	0.04	0.42	0.03	0.08	0.11
Dividend Per Share	0.286	0.286	0.204	0.170	-	-
Dividend Growth	39.98%	39.98%	19.99%	-	-	-
Gross Margin	35.98%	39.78%	39.70%	35.60%	40.09%	45.44%
Operating Margin	18.80%	24.90%	24.85%	23.16%	26.53%	32.98%
Profit Margin	18.45%	23.90%	24.40%	21.09%	22.38%	27.35%
Free Cash Flow Margin	2.46%	2.20%	25.01%	1.35%	4.61%	7.13%
EBITDA	165.82	215.99	190.69	167.38	157.19	160.77
EBITDA Margin	24.73%	29.73%	29.27%	26.68%	30.59%	37.12%
D&A For EBITDA	39.77	35.09	28.84	22.06	20.86	17.95
EBIT	126.05	180.91	161.85	145.31	136.33	142.82
EBIT Margin	18.80%	24.90%	24.85%	23.16%	26.53%	32.98%
Effective Tax Rate	12.64%	12.33%	13.23%	7.82%	12.97%	13.80%
Revenue as Reported	670.43	726.44	651.44	627.36	513.84	-
Advertising Expenses	-	0.85	0.51	0.2	0.28	0.19

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.